RarePipelinepeopleInnovationCollaborationCareersFinance Advance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Annual General Meeting of Hansa Medical rescheduled to May 14, 2012

15 Feb 2012, 15:30
Regulatory information

The Hansa Medical Annual General Meeting has previously been announced to take place on May 10. The Annual General Meeting of Hansa Medical has been rescheduled to Monday the 14th of May, 2012 at 18:00 in Hörsalen at Scheelevägen 22 in Lund, Sweden.

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: 46 707 17 54 77
E-mail: emanuel.bjorne@hansamedical.com

Hansa Medical is a biopharmaceutical development company focused on inflammation. The company develops innovative biopharmaceuticals and diagnostics in partnership with major companies with market presence as well as under full Hansa Medical management. At present, three primary product candidates are in development; IdeS, EndoS and HMD-301. Novel research projects and product candidates are generated through academic collaborations and in-house development. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium Nordic AB is Certified Adviser to Hansa Medical.